What's in Novo Nordisk's pipeline?

Novo Nordisk has 192 drugs in our index: 50 marketed, 0 filed, 30 in Phase 3, 22 in Phase 2, 90 in Phase 1.

Which companies overlap with Novo Nordisk's portfolio?

Top competitors by shared drug class: Sanofi, AstraZeneca, Eli Lilly and Company, Merck Sharp & Dohme LLC, GlaxoSmithKline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/novo-nordisk.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Novo Nordisk — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novo Nordisk (NVO) pipeline: 50 marketed, 0 filed, 30 Phase 3, 22 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

NVO (NYSE) 50 marketed 0 filed 30 Phase 3 22 Phase 2 90 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Rivfloza	NEDOSIRAN	marketed		LDHA mRNA	Metabolic	2025-01-01
Alhemo	CONCIZUMAB	marketed	Tissue Factor Pathway Inhibitor Antagonist [EPC]		Rare Disease	2024-01-01
Sogroya	SOMAPACITAN	marketed		Growth hormone receptor	Metabolic	2020-01-01
Ozempic	semaglutide	marketed	GLP-1 Receptor Agonist [EPC]	GLP-1 receptor	Metabolic	2017-01-01
Tresiba	INSULIN DEGLUDEC	marketed	Insulin Analog [EPC]	Insulin receptor	Metabolic	2015-01-01
Novoeight	TUROCTOCOG ALFA	marketed			Rare Disease	2013-01-01
Novothirteen	CATRIDECACOG	marketed			Metabolic	2012-01-01
Levemir	INSULIN DETEMIR	marketed	Insulin Analog [EPC]	Insulin receptor	Metabolic	2005-01-01
Novolog	INSULIN ASPART	marketed	Insulin Analog [EPC]	Insulin receptor	Metabolic	2000-01-01
Prandin	repaglinide	marketed	Glinide [EPC]	ATP-binding cassette sub-family C member 8	Metabolic	1997-01-01
Eptacog Alfa	EPTACOG ALFA (ACTIVATED)	marketed			Rare Disease	1996-01-01
Glucobay®	Glucobay®	marketed

Therapeutic area mix

Diabetes · 30
Metabolic · 9
Other · 8
Diabetes, Obesity · 3
Rare Disease · 3
Hematology · 2
Cardiovascular · 2
Hematology/Rare Blood Disorders · 2
Hematology/Oncology · 1
Diabetes, Obesity, Cardiovascular · 1

Recent regulatory actions (last 90 days)

2026-02-24 — Victoza · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2026-07-17 — Ozempic · 9775953 · US
2026-07-17 — Ozempic · 10220155 · US
2026-07-17 — Ozempic · 11097063 · US
2026-07-17 — Ozempic · 8920383 · US
2026-08-03 — Ozempic · RE46363 · US
2027-02-27 — Ozempic · 9687611 · US
2027-09-27 — Ozempic · 9457154 · US
2031-12-05 — Ozempic · 8129343 · US
2031-12-16 — Ozempic · 11382957 · US
2031-12-16 — Ozempic · 10086047 · US
2031-12-16 — Ozempic · 10960052 · US
2031-12-16 — Ozempic · 9278123 · US
2032-02-01 — Ozempic · 9132239 · US
2033-03-15 — Ozempic · 10933120 · US
2033-06-21 — Ozempic · 9764003 · US
2033-06-21 — Ozempic · 10335462 · US
2034-05-02 — Ozempic · 10278923 · US
2037-01-09 — Victoza · 9968659 · Method of Use · US
2037-07-09 — Victoza · 9968659*PED · Compound · US
2038-08-24 — Ozempic · 10888605 · US
2041-02-17 — Ozempic · 11318191 · US

Competitive overlap (companies sharing drug classes)

Sanofi · 7 shared drug classes
AstraZeneca · 6 shared drug classes
Eli Lilly and Company · 6 shared drug classes
Merck Sharp & Dohme LLC · 4 shared drug classes
GlaxoSmithKline · 4 shared drug classes
Hanmi Pharmaceutical Company Limited · 4 shared drug classes
Daewoong Pharmaceutical Co. LTD. · 3 shared drug classes
Geropharm · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Novo Nordisk:

Cite this brief

Drug Landscape (2026). Novo Nordisk — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/novo-nordisk. Accessed 2026-05-17.